AstraZeneca's (AZN) Enhertu has been approved by the European Commission for treating adults with previously treated HER2-positive unresectable or metastatic solid tumors who have no satisfactory treatment options.
The approval was based on phase 2 studies showing clinically meaningful response rates in patients with HER2-positive tumors across multiple cancer types, it said.
Enhertu is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.